Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,024.09 20.57 (1.97%) as of 4:30 Wed 7/3


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 107.21(B)
Last Volume: 378,341 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 191,758 236,826 311,409 468,643
Total Sell Value $188,359,854 $231,314,072 $294,701,490 $404,818,815
Total People Sold 7 13 16 18
Total Sell Transactions 16 39 65 127
End Date 2024-04-04 2024-01-02 2023-07-04 2022-07-04

   
Records found: 2433
  Page 66 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Terifay Robert J SVP Commercial   •       –      –    2012-12-18 4 OE $16.80 $99,994 D/D 5,952 15,324     -
   Sing George L Director   –       •      –    2012-12-17 4 GA $0.00 $0 I/I 10,000 10,000     -
   Sing George L Director   –       •      –    2012-12-17 4 GD $0.00 $0 D/D 10,000 112,772     -
   Goldberg Murray A SVP Fin & Admin CFO Asst Secy   •       –      –    2012-12-17 4 GD $0.00 $0 I/I 3,400 750     -
   Goldberg Murray A SVP Fin & Admin CFO Asst Secy   •       –      –    2012-12-17 4 OE $20.32 $37,592 D/D 1,850 66,470     -
   Mccorkle Douglas S VP Controller & Asst Treasurer   •       –      –    2012-12-17 4 AS $178.19 $179,198 D/D (1,000) 4,000     -
   Mccorkle Douglas S VP Controller & Asst Treasurer   •       –      –    2012-12-17 4 OE $16.80 $84,000 D/D 5,000 4,200     -
   Yancopoulos George EVP CSO Pres Regen Res Labs   •       •      –    2012-12-17 4 D $179.13 $42,728,775 D/D (238,535) 1,066,484     -
   Yancopoulos George EVP CSO Pres Regen Res Labs   •       •      –    2012-12-17 4 OE $109.29 $1,133,228 D/D 10,369 1,304,811     -
   Stahl Neil SVP Res and Devel Sciences   •       –      –    2012-12-17 4 OE $16.80 $99,994 D/D 5,952 48,988     -
   Goldberg Murray A SVP Fin & Admin CFO Asst Secy   •       –      –    2012-12-14 4 D $179.13 $825,252 D/D (4,607) 64,620     -
   Yancopoulos George EVP CSO Pres Regen Res Labs   •       •      –    2012-12-14 4 D $179.13 $6,876,980 D/D (38,391) 1,294,650     -
   Stahl Neil SVP Res and Devel Sciences   •       –      –    2012-12-14 4 D $179.13 $1,502,184 D/D (8,386) 43,036     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2012-12-11 4 AS $184.85 $623,268 D/D (3,368) 10,500     -
   Goldberg Murray A SVP Fin & Admin CFO Asst Secy   •       –      –    2012-12-10 4 GD $0.00 $0 I/I 6,100 4,150     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2012-12-10 4 D $182.68 $754,834 D/D (4,132) 13,868     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2012-12-10 4 OE $30.63 $229,725 D/D 7,500 18,000     -
   Goldberg Murray A SVP Fin & Admin CFO Asst Secy   •       –      –    2012-12-07 4 GD $0.00 $0 I/I 4,250 10,250     -
   Goldberg Murray A SVP Fin & Admin CFO Asst Secy   •       –      –    2012-12-03 4 GA $0.00 $0 I/I 14,500 14,500     -
   Goldberg Murray A SVP Fin & Admin CFO Asst Secy   •       –      –    2012-12-03 4 GD $0.00 $0 D/D 14,500 69,227     -
   Roberts William VP Regulat Dev & Med Safety   •       –      –    2012-11-30 4 S $177.43 $2,078,975 I/I (11,500) 0     -
   Stahl Neil SVP Res and Devel Sciences   •       –      –    2012-11-30 4 OE $20.32 $199,994 D/D 9,483 51,422     -
   Stahl Neil SVP Res and Devel Sciences   •       –      –    2012-11-30 4 S $181.01 $3,110,114 D/D (17,182) 41,939     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2012-11-30 4 AS $180.08 $705,228 D/D (3,904) 10,500     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2012-11-29 4 D $182.20 $807,146 D/D (4,430) 14,404     -
  2433 Records found
  Previous  60  61  62  63  64  65  66  67  68  69  Next   
  Page 66 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us